Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 59 min 7 sec ago

PENTAX Medical Reaffirms Commitment to Work with FDA and Industry Partners To Address Duodenoscope Infection Issues

Thu, 05/14/2015 - 13:54
MONTVALE, N.J., May 14, 2015 -- (Healthcare Sales & Marketing Network) -- As the FDA Advisory Panel on Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee prepares to meet, PENTAX Medical affirms its commitment to work wit...
Devices, Gastroenterology, Urology
PENTAX Medical

EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015

Thu, 05/14/2015 - 13:41
BOSTON, May 14, 2015 -- (Healthcare Sales & Marketing Network) -- EPIRUS Biopharmaceuticals, Inc. (EPRS) and mAbxience, a biopharmaceutical company specialized in research, development and manufacturing of biosimilars, entered into a development and future...
Biopharmaceuticals, Distribution
EPIRUS Biopharmaceuticals, mAbxience, biosimilar, infliximab

St. Jude Medical Expands Portfolio of MRI-Compatible Devices to High Voltage in Europe

Wed, 05/13/2015 - 22:19
CE Mark approvals further strengthen the company’s portfolio of MRI-compatible devices ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical device company, today announced CE Mark approval of expanded l...
Devices, Cardiology, Regulatory
St. Jude Medical, Assurity MRI, Endurity MRI

Mederi Therapeutic's Stretta Becomes World's Most Widely-Used Non-Surgical Treatment For Chronic GERD

Wed, 05/13/2015 - 14:49
18,000 Stretta procedures performed since introduction, making Stretta the safest and most widely used endoluminal therapy for GERD Stretta expands reach with regulatory approvals added in large international markets NORWALK, Conn. , May 13, 2015 -- ...
Devices, Gastroenterology
Mederi Therapeutics, Stretta , GERD

Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development

Wed, 05/13/2015 - 14:41
New Executive Brings Wealth of Experience and Impressive Track Record as Company Approaches Pivotal Trial NEW YORK, NY--(Healthcare Sales & Marketing Network) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company&q...
Biopharmaceuticals, Personnel
Actinium Pharmaceuticals

Sorin And Cyberonics Announce Executive Leadership Team For The New Company Upon Close Of Merger

Tue, 05/12/2015 - 15:45
MILAN and HOUSTON, May 12, 2015 -- (Healthcare Sales & Marketing Network) -- Sorin S.p.A., (MTA; Reuters Code: SORN.MI "Sorin"), a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc. (NASD...
Devices, Neurology, Mergers & Acquisitions, Personnel
Cyberonics, Sorin Group, neuromodulation

Paradigm Spine, LLC Announces The Publication Of Long-term Results Of Level 1 Data For coflex(R) Interlaminar Stabilization(R)

Tue, 05/12/2015 - 15:40
NEW YORK, May 12, 2015 -- (Healthcare Sales & Marketing Network) -- Paradigm Spine, LLC, a leader in providing solutions for the treatment of advanced degenerative lumbar spinal stenosis announces publication on May 11, 2015 by Hyun Bae, M.D., et al of &q...
Devices, Orthopaedic, Neurosurgery
Paradigm Spine, coflex, Interlaminar Stabilization

Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

Tue, 05/12/2015 - 14:26
SAN DIEGO, May 12, 2015 -- (Healthcare Sales & Marketing Network) -- Aspyrian Therapeutics Inc., a drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform, today announced the U.S...
Biopharmaceuticals, Oncology, FDA
Aspyrian Therapeutics, Photoimmunotherapy

Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer

Tue, 05/12/2015 - 14:19
Evofosfamide is an investigational compound currently in Phase III trials Advanced pancreatic cancer is second indication to receive FDA fast track designation for evofosfamide ROCKLAND, Massachusetts, May 12, 2015 -- (Healthcare Sales & Marketing Ne...
Biopharmaceuticals, Oncology, FDA
EMD Serono, Merck KGaA, evofosfamide, pancreatic cancer

Autonomic Technologies Raises USD 38M in a Transatlantic Series D Financing

Tue, 05/12/2015 - 14:03
REDWOOD CITY, CA--(Healthcare Sales & Marketing Network) - Autonomic Technologies™, Inc. (ATI™), developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches, today announced the closing of a series D round of financing for $38M. Th...
Devices, Neurology, Venture Capital, Personnel
Autonomic Technologies, Pulsante, microstimulator

FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma

Mon, 05/11/2015 - 15:42
PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review ST. HELIER, Jersey--(Healthcare Sales & Marketing Network)--Novocure, a commercial stage o...
Devices, Oncology, FDA
Novocure, Tumor Treating Fields, Optune, glioblastoma

Cartiva, Inc. Closes $8.5 Million Financing

Mon, 05/11/2015 - 15:37
ALPHARETTA, Ga.--(Healthcare Sales & Marketing Network)--Cartiva, Inc., (Company) a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that it has secured $8.5 million in an oversubscribed Series D ...
Devices, Venture Capital, Personnel
Cartiva, cartilage implant, cartilage

PaxVax Appoints Nima Farzan Chief Executive Officer

Mon, 05/11/2015 - 15:34
REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that the Board of Directors has appointed Nima Farzan Chief Executive Officer and President. In this r...
Biopharmaceuticals, Personnel
PaxVax, Vivotif, vaccine

Kane Biotech Announces Change in Executive Leadership

Mon, 05/11/2015 - 14:30
WINNIPEG, MANITOBA--(Healthcare Sales & Marketing Network) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announced Gord Froehlich...
Biopharmaceuticals, Personnel
Kane Biotech, microbial biofilms

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong